83.30
-1.61 (-1.89%)
| Previous Close | 84.90 |
| Open | 83.60 |
| Volume | 472,117 |
| Avg. Volume (3M) | 1,689,826 |
| Market Cap | 6,449,851,392 |
| Price / Book | 8.74 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Operating Margin (TTM) | -4,865.98% |
| Diluted EPS (TTM) | -3.45 |
| Quarterly Revenue Growth (YOY) | -17.40% |
| Total Debt/Equity (MRQ) | 269.12% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | -152.60 M |
| Levered Free Cash Flow (TTM) | -87.22 M |
| Return on Assets (TTM) | -48.60% |
| Return on Equity (TTM) | -196.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Abivax SA | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Institutions | 50.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Great Point Partners I Lp | 30 Jun 2025 | 1,291,617 |
| Saturn V Capital Management Lp | 30 Jun 2025 | 622,479 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 114.00 (JMP Securities, 36.86%) | Buy |
| Median | 106.50 (27.86%) | |
| Low | 101.00 (Morgan Stanley, 21.26%) | Buy |
| 101.00 (LifeSci Capital, 21.26%) | Buy | |
| 101.00 (Guggenheim, 21.26%) | Buy | |
| Average | 106.83 (28.26%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 77.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 25 Sep 2025 | 114.00 (36.86%) | Buy | 82.00 |
| 23 Jul 2025 | 95.00 (14.05%) | Buy | 68.60 | |
| Morgan Stanley | 12 Sep 2025 | 101.00 (21.26%) | Buy | 84.01 |
| BTIG | 09 Sep 2025 | 112.00 (34.46%) | Buy | 89.25 |
| Piper Sandler | 29 Jul 2025 | 112.00 (34.46%) | Buy | 69.80 |
| 23 Jul 2025 | 70.00 (-15.96%) | Buy | 68.60 | |
| Guggenheim | 23 Jul 2025 | 101.00 (21.26%) | Buy | 68.60 |
| LifeSci Capital | 23 Jul 2025 | 101.00 (21.26%) | Buy | 68.60 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |